Metropolitan Life Insurance Company (MetLife)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RXDX Stock Details RXDX Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell
2023 Q1	$202K	Sell
2022 Q4	$238K	Buy
2022 Q3	$106K	Hold
2022 Q2	$50.6K	Hold
2022 Q1	$67.7K	Sell
2021 Q4	$329K	Buy
2021 Q3	$88.1K	Buy